Global Inequalities in Clinical Trials Participation
Lou, Díaz-Faes, He, Liu, Larivière · econ.GN,cs.CE,q-fin.EC · 2026-08-04 · 原文 · 证据态 未学
Clinical trials are fundamental to the production of medical evidence and determine who gains access to experimental therapies. Although prior work has long documented inequalities in global clinical trial participation, a systematic quantification of the relative contributions of country-level factors and disease burden remains absent. This paper analyzes inequality in participation across 78,117 randomized controlled trials (RCTs) spanning 16 major disease categories from 2000 to 2024. Linking 185.6 million RCTs participants to country-level disease burden, the paper shows that inequalities in RCTs participation are predominantly explained by country-level factors rather than disease burden. Country-level factors account for 88.9% of the variation in participation, whereas disease and temporal effects contribute marginally. Removing entire disease categories, including those traditionally underfunded, has little effect on overall inequality. Instead, participation is highly concentrated geographically, with a small group of Global North countries enrolling a disproportionate share of participants across nearly all diseases. These patterns persist despite decades of disease-target
讲义
讲义·推断 依据「原文」自动生成的结构化摘要（推断），非原文表述；以原文为准。
1. 人话版
Clinical trials are fundamental to the production of medical evidence and determine who gains access to experimental therapies.
Although prior work has long documented inequalities in global clinical trial participation, a systematic quantification of the relative contributions of country-level factors and disease burden remains absent.
2. 领域脉络
本文类目：econ.GN、cs.CE、q-fin.EC，属于其所在研究脉络的最新进展。
3. 机制拆解
摘要未展开方法细节——精读时重点看方法/模型部分。
4. 证据与数字
This paper analyzes inequality in participation across 78,117 randomized controlled trials (RCTs) spanning 16 major disease categories from 2000 to 2024.
Linking 185.6 million RCTs participants to country-level disease burden, the paper shows that inequalities in RCTs participation are predominantly explained by country-level factors rather than disease burden.
Country-level factors account for 88.9% of the variation in participation, whereas disease and temporal effects contribute marginally.
5. 反例与边界
摘要未声明局限与反例——这是需要警惕的信号，精读时先问边界。
6. 跨领域连接与意外收获
横跨 3 个类目（econ.GN、cs.CE、q-fin.EC），关注其在你兴趣板块间的迁移面。
7. 可复用方法
把本文机制与你手头项目对照，找一个两周内能验证的最小实验。
8. 术语表
精读时把不熟的术语记入此处，作为下次回忆的锚点。
主动回忆
先合上内容自己复述，再点「显示」核对，然后如实自评。评分即时进 FSRS 排程。
讲义·推断 依据「原文」自动生成的结构化摘要（推断），非原文表述；以原文为准。
1. 人话版
Clinical trials are fundamental to the production of medical evidence and determine who gains access to experimental therapies.
Although prior work has long documented inequalities in global clinical trial participation, a systematic quantification of the relative contributions of country-level factors and disease burden remains absent.
2. 领域脉络
本文类目：econ.GN、cs.CE、q-fin.EC，属于其所在研究脉络的最新进展。
3. 机制拆解
摘要未展开方法细节——精读时重点看方法/模型部分。
4. 证据与数字
This paper analyzes inequality in participation across 78,117 randomized controlled trials (RCTs) spanning 16 major disease categories from 2000 to 2024.
Linking 185.6 million RCTs participants to country-level disease burden, the paper shows that inequalities in RCTs participation are predominantly explained by country-level factors rather than disease burden.
Country-level factors account for 88.9% of the variation in participation, whereas disease and temporal effects contribute marginally.
5. 反例与边界
摘要未声明局限与反例——这是需要警惕的信号，精读时先问边界。
6. 跨领域连接与意外收获
横跨 3 个类目（econ.GN、cs.CE、q-fin.EC），关注其在你兴趣板块间的迁移面。
7. 可复用方法
把本文机制与你手头项目对照，找一个两周内能验证的最小实验。
8. 术语表
精读时把不熟的术语记入此处，作为下次回忆的锚点。